ClinicalTrials.gg
CompletedNCT04728035Updated Jul 26, 2024

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

A Phase 1 interventional study of Irinotecan Liposome Injection in Advanced Breast Cancer, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
119
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited — 16 open to participants now, 18 under way, 10 of them phase 3. Breast Neoplasms · CSPC Pharmaceutical Group Limited.

Enrollment
17th of 26
119 · median 270
Started
2021
with 1 other
Phase 1
3 of 26
1 open now
Registered
4th of 26
by date

Among the 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited, this one is the 17th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 1, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

This study is an open-label, single-arm, phase I study of irinotecan liposome injection in patients with advanced breast cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan liposome injection in patients with advanced breast cancer.

Read the detailed description

This is an open-label, single-arm, phase I study with a dose-escalation phase (part 1) and a dose-expansion phase (part 2). In part 1, patients will receive irinotecan liposome injection (CSPC) at the initial starting dose until progression or unacceptable toxicity. Dosages will be escalated by certain increments in subsequent cohorts. Once the appropriate dose has been established in part 1, patients will be enrolled into two expansion cohorts in part 2.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients 1.Female aged between 18 and 75 years.

2. or cytologically confirmed breast cancer.

3.At least one according to 1.1.

4.The time interval between the end of the last anti-tumor treatment and the first administration of irinotecan liposome injection is restricted as follows:

(1) More than 6 weeks for nitrosoureas (such as carmustine, lomustine, etc.) or mitomycin C.

(2) More than 3 weeks for cytotoxic chemotherapeutics, immunotherapy such as /PD-L1 and biotherapy.

(3) More than 2 weeks (five half-lives, whichever is longer) for oral fluorouracil, oral small molecule targeted drugs, and endocrine therapy.

(4) More than 2 weeks for Radiotherapy. (5) More than 2 Weeks for traditional Chinese medicine with anti-tumor indications.

5. (ECOG) performance status 0 to 2.

6. >3 months.

7.Patient should not receive blood transfusion or supportive care (eg. EPO, G-CSF or others) within 14 days before the initiate dose, and laboratory test should meet the following criteria: neutrophile count ≥1.5×10\^9/L count ≥100×10\^9/L ≥90 g/L or ≥5.6 mmol/L serum creatinine ≤1.5× and rate ≥50 mL/min total ≤1×ULN and ALT ≤2.5×ULN

8.Patient with must agree to use adequate from the signing of to at least 6 months after the trial completion and have a negative serum pregnancy test within 7 days before enrollment.

9.Ability to understand and the willingness to sign a written informed consent.

Additional criteria for dose escalation and cohort 1 in dose expansion

1.Meet the molecular classification criteria for triple-negative breast cancer.

2.Patients with locally recurrent or disease who have received at least two prior chemotherapeutic regimens for breast cancer and had failed to prior chemotherapy due to progression or intolerable toxicity:

(1)Early or adjuvant chemotherapy for localized disease that progresses to unresectable locally advanced or metastatic disease within 12 months after completion is one of the permitted previous chemotherapy regimens.

(2)PARP inhibitor for patients with germline BRCA1/BRCA2 mutations who have been treated with approved PARP inhibitors, is one of the permitted prior chemotherapy regimens.

3.Previous treatment with taxanes and anthracyclines was required regardless of the stage of disease (neoadjuvant, adjuvant or palliative). Those who have or intolerance to a certain drug above should receive at least one cycle of treatment with this drug, and can be exempted from the requirements for the use of this drug.

Additional criteria for cohort 2 in dose expansion

1. negative breast cancer defined as 0 - 1+ by immunohistochemistry or FISH negative result.

2.Evidence of new and/or progressive following previous radiotherapy (WBRT and/or SRS and/or gamma knife) and/or surgery.

3.At least one measurable brain lesion (≥10 mm on T1-weighted, gadolinium-enhanced magnetic resonance imaging).

Exclusion criteria

Exclusion Criteria

  1. Patients who have received any drug within 4 weeks of the first dose of the study drug.
  2. Patients who have undergone major organ surgery (excluding needle ) or have significant trauma within 4 weeks prior to the first dose of the study drug, or have a schedule for major surgery during the trial.
  3. Patients who have concomitant use of strong inhibitors or inducers within 2 weeks prior to receiving the first dose of irinotecan liposome injection, or CYP3A4 inhibitors or UGT1A1 inhibitors within 1 week prior to receiving the first dose of irinotecan liposome injection, or those who could not suspend the above drugs during the study.
  4. Patients who received systemic (prednisone >10 mg/day or equivalent dose of the similar drugs) or other agents within 14 days before the first dose of the study drug. Except for local, ocular, intra-articular, intranasal, and inhaled glucocorticoids, short term use of glucocorticoids for preventive treatment (e.g., prevention of contrast allergy). Cohort 2 in dose expansion is not limited.
  5. Patients who have received prior topoisomerase I inhibitor treatment, including irinotecan or other investigational agents.
  6. Known ( 5.0≥3) to any of the components of irinotecan liposome injection, or other liposomal products.
  7. Patients with central Nervous System (CNS) meet any of the following criteria: Cohort 2 in dose expansion is not limited.

(1)Patients who have developed new or progressive following cranial radiation or surgery.

(2)Patients with the symptomatic Central Nervous System (CNS) metastasis who have used cortisol, radiotherapy, dehydration drugs, etc. to control symptoms in the past two weeks.

(3)Patients with carcinomatous meningitis.

(4)Patients with brainstem (midbrain, pons, medulla oblongata) metastasis.

(5)Patients have other evidence indicates that the patient's central nervous system metastasis or meningeal metastasis has not been controlled and is judged unsuitable for enrollment by the investigator.

8.Patients who have pulmonary lymphatic dissemination and metastasis, leading to dyspnea at rest, may need to be combined with other treatments, such as oxygen inhalation, which is judged not suitable for enrollment by the investigator.

9.Prior radiation therapy encompassing more than 30% of bone marrow.

10.Patients have unresolved adverse reactions > grade 1 (CTCAE 5.0) from previous anti-tumor treatment (except for the peripheral neuropathy \< grade 2, alopecia, and other toxicity judged no safety risk by investigators).

11.History of disease, immunodeficiency (including test positive), or other acquired or congenital immunodeficiency, or organ transplantation.

12.Patients with known Virus (HBV DNA>2000 IU/ml), Virus (anti-HCV positive), or other uncontrolled active infections.

13.Chronic gastrointestinal dysfunction with diarrhea as the main symptom, such as Crohn's disease, ulcerative colitis, malabsorption or Diarrhea ≥ grade 1, intestinal obstruction, or other gastrointestinal diseases of clinical significance as judged by the investigators.

14.Previous in the past five years (except basal cell carcinoma, squamous cell carcinoma, superficial bladder carcinoma, local prostate carcinoma, carcinoma in situ of cervical, or of others that have been radically resected and have not recurred).

15.History of serious cardiovascular disease, including but not limited to:

  1. Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, etc.
  2. Patients with prolonged /QTc interval in baseline (ECG) (QTcF > 480 ms, Fridericia formula: QTcF = QT/RR0.33, RR = 60/heart rate).
  3. Patients with myocardial infarction, angina pectoris, coronary angioplasty or stent, deep vein thrombosis, stroke within 6 months before enrollment.
  4. Baseline echocardiography (ECHO) or cardiac radionuclide scanning () techniques showed left ventricular ejection fraction (LVEF) ≤ 50%, or grade Ⅲ and above.
  5. Poorly controlled hypertension (systolic blood pressure≥150 mmHg and/or diastolic blood pressure≥ 95 mmHg with optimal treatment.
  6. Previous or current cardiomyopathy.
  7. Patients with abnormal electrocardiogram (ECG)according to the investigator's assessment.
  1. Uncontrolled third lacunar effusion, improper for enrollment by investigator's assessment.
  1. Patients with alcohol or drug dependence.
  1. Pregnant or lactating women.

19.History of explicit neurological or psychiatric disorders, including epilepsy or dementia.

  1. Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration, or interfere with the interpretation of safety results.
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Dose escalation (part 1)

    Patients will receive irinotecan liposome injection (CSPC) at the initial starting dose until progression or unacceptable toxicity.

    Drug: Irinotecan Liposome Injection

  • Experimental
    Dose expansion (part 2)

    Once the appropriate dose has been established in Part 1, patients will be enrolled into two expansion cohorts according to the sub-type of breast cancer.

    Drug: Irinotecan Liposome Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs)

    The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.

    Time frame: Up to six months after the last patient's first administration

  2. Dose limiting toxicity (DLT)

    DLT will be assessed according to NCICTCAE v5.0.

    Time frame: Up to 28 days post-product injection

  3. Maximum Tolerated Dose (MTD, if available)

    MTD was defined as the previous dose level at which 2 out of 6 patients experienced a DLT.

    Time frame: Up to 28 days post-product injection

  4. Recommended Phase 2 Dose (RP2D)

    RP2D was defined as the dose level chosen by the sponsor (in consultation with the investigators) for the dose expansion arms, based on safety, tolerability data collected during the dose escalation portion of the study.

    Time frame: Up to the end of the part 1

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage of patients who achieve a complete response (CR) or partial response (PR) based on the modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

    Time frame: Up to six months after the last patient's first administration

  2. Progression-Free Survival (PFS)

    Time from date of the first dose to date of recorded disease progression or death, whichever occurs first.

    Time frame: Up to six months after the last patient's first administration

  3. Disease Control Rate (DCR)

    The percentage of patients who achieve a CR, PR or stable disease (SD) based on the modified RECIST 1.1.

    Time frame: Up to six months after the last patient's first administration

  4. Duration of Response (DOR)

    Time from first documented response (CR or PR whichever occurs first, based on investigator's assessment using RECIST 1.1) to date of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to six months after the last patient's first administration

  5. Overall survival (OS)

    Time from date of the first dose to date of death from any cause.

    Time frame: Up to six months after the last patient's first administration

  6. CNS objective response rate (CNS ORR)

    The percentage of patients who achieve a CR or PR based on Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) in Cohort 2 of dose expansion.

    Time frame: Up to six months after the last patient's first administration

  7. CNS clinical benefit rate (CNS CBR)

    The percentage of patients who achieve a CR, PR or SD based on RANO-BM in Cohort 2 of dose expansion.

    Time frame: Up to six months after the last patient's first administration

  8. The Area under the concentration-time curve from time zero to infinity (AUCinf)

    AUCinf of total irinotecan,wrapped irinotecan, free irinotecan and SN-38 will be measured for the test product .

    Time frame: -30minutes~168hours

  9. The Maximum observed plasma concentration (Cmax)

    Cmax of total irinotecan,wrapped irinotecan, free irinotecan and SN-38 will be measured for the test product .

    Time frame: -30 minutes~168 hours

  10. The terminal elimination half-life (T1/2)

    T1/2 of total irinotecan,wrapped irinotecan, free irinotecan and SN-38 will be measured for the test product.

    Time frame: -30 minutes~168 hours

  11. The time to maximum concentration (Tmax)

    Tmax of total irinotecan,wrapped irinotecan, free irinotecan and SN-38 will be measured for the test product .

    Time frame: -30minutes~168 hours

  12. The Apparent volume of distribution (Vd)

    Vd of total irinotecan will be measured for the test product.

    Time frame: -30 minutes~168 hours

Other outcomes

  1. UGT1A1 gene polymorphism and Topoisomerase I (Topo I) expression

    UGT1A1 gene polymorphism and Topoisomerase I (Topo I) expression

    Time frame: Up to six months after the last patient's first administration

07

Study locations

1 site
  • Cancer Hosptial of CAMS
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jun 2023, 24 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 24 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 28, 2021
StartActual
May 31, 2021
Primary completionActual
Jun 5, 2023
CompletionActual
Jun 5, 2024
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04728035
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
May 31, 2021
Primary completion
Jun 5, 2023
Completion
Jun 5, 2024
Last update
Jul 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion